Duan‐Bo Shi

1.0k total citations
28 papers, 582 citations indexed

About

Duan‐Bo Shi is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Duan‐Bo Shi has authored 28 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Duan‐Bo Shi's work include Cancer-related molecular mechanisms research (12 papers), MicroRNA in disease regulation (7 papers) and RNA modifications and cancer (7 papers). Duan‐Bo Shi is often cited by papers focused on Cancer-related molecular mechanisms research (12 papers), MicroRNA in disease regulation (7 papers) and RNA modifications and cancer (7 papers). Duan‐Bo Shi collaborates with scholars based in China and United States. Duan‐Bo Shi's co-authors include Peng Gao, Ai‐Yan Xing, Hui Zhang, Yawen Wang, Ran‐Ran Ma, Haiting Liu, Chen Xu, Xiangyu Guo, Ya‐Wen Wang and Chao Gao and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Duan‐Bo Shi

27 papers receiving 579 citations

Peers

Duan‐Bo Shi
Liang Deng China
M. Ángeles Villaronga Spain
Ritu Kulshrestha India
Yifeng Cui China
Bethany C. Prudner United States
Ya‐Wen Wang China
Xuetao Li China
Junhao Mu China
Elisa Cattaneo Italy
Rujun Mo China
Liang Deng China
Duan‐Bo Shi
Citations per year, relative to Duan‐Bo Shi Duan‐Bo Shi (= 1×) peers Liang Deng

Countries citing papers authored by Duan‐Bo Shi

Since Specialization
Citations

This map shows the geographic impact of Duan‐Bo Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Duan‐Bo Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Duan‐Bo Shi more than expected).

Fields of papers citing papers by Duan‐Bo Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Duan‐Bo Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Duan‐Bo Shi. The network helps show where Duan‐Bo Shi may publish in the future.

Co-authorship network of co-authors of Duan‐Bo Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Duan‐Bo Shi. A scholar is included among the top collaborators of Duan‐Bo Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Duan‐Bo Shi. Duan‐Bo Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Hongming, Duan‐Bo Shi, Huamin Qin, et al.. (2025). When multiple instance learning meets foundation models: Advancing histological whole slide image analysis. Medical Image Analysis. 101. 103456–103456. 6 indexed citations
3.
4.
Liu, Haiting, Feng Li, Xiangyu Guo, et al.. (2023). LncRNA LY6E-DT and its encoded metastatic-related protein play oncogenic roles via different pathways and promote breast cancer progression. Cell Death and Differentiation. 31(2). 188–202. 15 indexed citations
5.
Hou, Feng, Duan‐Bo Shi, Xiangyu Guo, et al.. (2023). HRCT1, negatively regulated by miR-124-3p, promotes tumor metastasis and the growth of gastric cancer by activating the ERBB2-MAPK pathway. Gastric Cancer. 26(2). 250–263. 7 indexed citations
6.
Song, Li, Qian Xu, Xin Dai, et al.. (2023). Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology. 30(6). 3594–3602. 16 indexed citations
7.
Sun, Yujing, Junyi He, Duan‐Bo Shi, et al.. (2020). Elevated ZBTB7A expression in the tumor invasive front correlates with more tumor budding formation in gastric adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 147(1). 105–115. 9 indexed citations
8.
Sun, Yiting, Li Song, Wenbin Yu, et al.. (2020). CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR. Journal of Cancer. 11(9). 2667–2678. 10 indexed citations
9.
Liu, Haiting, Ran‐Ran Ma, Beibei Lv, et al.. (2020). LncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K/AKT signalling pathway by sponging miR-30b-3p in gastric cancer. British Journal of Cancer. 122(12). 1825–1836. 60 indexed citations
10.
Luan, Meng, Shanshan Shi, Duan‐Bo Shi, et al.. (2020). TIPRL, a Novel Tumor Suppressor, Suppresses Cell Migration, and Invasion Through Regulating AMPK/mTOR Signaling Pathway in Gastric Cancer. Frontiers in Oncology. 10. 1062–1062. 14 indexed citations
11.
Shi, Duan‐Bo, et al.. (2019). GAGE7B promotes tumor metastasis and growth via activating the p38δ/pMAPKAPK2/pHSP27 pathway in gastric cancer. Journal of Experimental & Clinical Cancer Research. 38(1). 124–124. 17 indexed citations
12.
13.
Liu, Haiting, Yawen Wang, Ai‐Yan Xing, et al.. (2017). Prognostic Value of microRNA Signature in Patients with Gastric Cancers. Scientific Reports. 7(1). 42806–42806. 14 indexed citations
14.
Li, Xiaomei, Chen Xu, Yawen Wang, et al.. (2017). Overexpression of TMPRSS4 promotes tumor proliferation and aggressiveness in breast cancer. International Journal of Molecular Medicine. 39(4). 927–935. 18 indexed citations
15.
Shi, Duan‐Bo, Ya‐Wen Wang, Ai‐Yan Xing, et al.. (2015). C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Letters. 369(2). 376–385. 56 indexed citations
16.
Wang, Yawen, Duan‐Bo Shi, Yamin Liu, et al.. (2014). Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma. Journal of Cancer Research and Clinical Oncology. 140(8). 1271–1281. 4 indexed citations
17.
Wang, Yawen, Duan‐Bo Shi, Chen Xu, Chao Gao, & Peng Gao. (2014). Clinicopathological Significance of MicroRNA-214 in Gastric Cancer and Its Effect on Cell Biological Behaviour. PLoS ONE. 9(3). e91307–e91307. 38 indexed citations
18.
Liu, Yamin, et al.. (2013). Expression of ZEB1 in breast carcinoma and its clinical significance. 29(6). 594–597. 1 indexed citations
19.
Xing, Ai‐Yan, Bin Wang, Duan‐Bo Shi, et al.. (2013). Deregulated expression of miR-145 in manifold human cancer cells. Experimental and Molecular Pathology. 95(1). 91–97. 34 indexed citations
20.
Xing, Ai‐Yan, Duan‐Bo Shi, Wei Liu, et al.. (2013). Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme. Experimental and Molecular Pathology. 94(3). 481–485. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liang Deng Breakdown of academic impact, for papers by M. Ángeles Villaronga Breakdown of academic impact, for papers by Ritu Kulshrestha Breakdown of academic impact, for papers by Yifeng Cui Breakdown of academic impact, for papers by Bethany C. Prudner Breakdown of academic impact, for papers by Ya‐Wen Wang Breakdown of academic impact, for papers by Xuetao Li Breakdown of academic impact, for papers by Junhao Mu Breakdown of academic impact, for papers by Elisa Cattaneo Breakdown of academic impact, for papers by Rujun Mo
Rankless by CCL
2026